For a patient taking Nugenix (testosterone booster), which laboratory tests should be monitored?

Monitoring for Patients Taking Nugenix

For patients taking Nugenix, no specific laboratory monitoring is required, as Nugenix is an over-the-counter dietary supplement containing acetaminophen, dextromethorphan, and phenylephrine—not actual testosterone. 1

Critical Distinction: Supplement vs. Prescription Testosterone

Nugenix is marketed as a "testosterone booster" but does not contain pharmaceutical testosterone. The FDA label reveals it contains only acetaminophen 325 mg, dextromethorphan 10 mg, and phenylephrine 5 mg per dose 1. These are common cold/flu medication ingredients, not hormones.

If Your Patient Believes They Need Testosterone Therapy

If your patient is taking Nugenix hoping to address symptoms of low testosterone, they likely need proper evaluation and potentially prescription testosterone replacement therapy (TRT). In that case, follow this monitoring protocol based on Endocrine Society guidelines 2:

Monitoring Protocol for Actual Testosterone Therapy

Baseline (Before Starting Treatment)

• Testosterone level (morning, fasting, repeated to confirm)
• Hematocrit/hemoglobin
• PSA and digital rectal exam (men ≥40 years with baseline PSA >0.6 ng/ml) 2
• Assess voiding symptoms and sleep apnea history 3

At 3-6 Months After Initiation

• Testosterone level (timing depends on formulation—see below)
• Hematocrit 2
• PSA and digital rectal exam (if indicated by age/baseline) 2
• Clinical assessment of symptom response and adverse effects 2

Annually Thereafter

• Testosterone level
• Hematocrit 2
• PSA and digital rectal exam (per age-appropriate screening guidelines) 2
• Clinical symptom assessment 2

Critical Safety Thresholds

Hematocrit Monitoring

Stop testosterone therapy if hematocrit >54% until it decreases to a safe level; evaluate for hypoxia and sleep apnea before reinitiating at a reduced dose 2. Baseline hematocrit >50% is a relative contraindication 2.

PSA Monitoring

Obtain urology consultation if 2:

• PSA increase >1.4 ng/ml within any 12-month period
• PSA velocity >0.4 ng/ml/year (after 6 months of therapy)
• Abnormal digital rectal examination
• Prostate symptom score (AUA/IPSS) >19

Common Pitfall: Over-the-Counter "Testosterone Boosters"

Testosterone boosters like Nugenix do not reliably increase testosterone levels and may carry hepatic risks. One case report documented hepatic dysfunction in an athlete using testosterone booster supplements 4. These products are not regulated like prescription medications and their efficacy is unproven.

What to Tell Your Patient

If your patient has genuine symptoms of hypogonadism (low libido, erectile dysfunction, fatigue, reduced muscle mass), they need:

1. Proper diagnosis with two morning testosterone measurements showing levels consistently <300 ng/dl
2. Prescription testosterone therapy if indicated—not over-the-counter supplements
3. Structured monitoring as outlined above to prevent serious complications like polycythemia and undetected prostate cancer

The bottom line: Nugenix requires no monitoring because it's not testosterone therapy. If your patient needs actual testosterone replacement, prescribe pharmaceutical testosterone and follow evidence-based monitoring protocols.